Valproate bismuth

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Valproate bismuth is a medication used to treat laryngitis.

Generic Name
Valproate bismuth
DrugBank Accession Number
DB13910
Background

Valproate bismuth is available in Canada in the over-the-counter medication Neo-Laryngobis.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 638.598
Monoisotopic: 638.30201
Chemical Formula
C24H45BiO6
Synonyms
  • Bismuth dipropylacetate

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofAngina••• ••••••••
Treatment ofGingivostomatitis••• ••••••••
Treatment ofLaryngitis••• ••••••••
Treatment ofPharyngitis••• ••••••••
Treatment ofSore throat••• ••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetophenazineAcetophenazine may increase the neurotoxic activities of Valproate bismuth.
AlfentanilThe risk or severity of serotonin syndrome can be increased when Alfentanil is combined with Valproate bismuth.
AlimemazineAlimemazine may increase the neurotoxic activities of Valproate bismuth.
AlmotriptanThe risk or severity of serotonin syndrome can be increased when Almotriptan is combined with Valproate bismuth.
AmantadineThe risk or severity of serotonin syndrome can be increased when Amantadine is combined with Valproate bismuth.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Neo Laryngobis EnfSuppository67.5 mgRectalLab Bio Chimique Inc.,Division Of Technilab Pharma Inc.1950-12-311997-08-22Canada flag
Neo-laryngobisSuppository135 mgRectalTEVA Canada Limited1950-12-31Not applicableCanada flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as methyl-branched fatty acids. These are fatty acids with an acyl chain that has a methyl branch. Usually, they are saturated and contain only one or more methyl group. However, branches other than methyl may be present.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Fatty acids and conjugates
Direct Parent
Methyl-branched fatty acids
Alternative Parents
Carboxylic acid salts / Monocarboxylic acids and derivatives / Carboxylic acids / Organic salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds / Organic cations
Substituents
Aliphatic acyclic compound / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Carboxylic acid salt / Hydrocarbon derivative / Methyl-branched fatty acid / Monocarboxylic acid or derivatives / Organic cation / Organic oxide
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
87PTX621FI
CAS number
60364-28-5
InChI Key
YZDVVHSLIPLZLO-UHFFFAOYSA-K
InChI
InChI=1S/3C8H16O2.Bi/c3*1-3-5-7(6-4-2)8(9)10;/h3*7H,3-6H2,1-2H3,(H,9,10);/q;;;+3/p-3
IUPAC Name
bismuth(3+) tris(2-propylpentanoate)
SMILES
[Bi+3].CCCC(CCC)C([O-])=O.CCCC(CCC)C([O-])=O.CCCC(CCC)C([O-])=O

References

General References
Not Available
ChemSpider
20137751
RxNav
324003

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SuppositoryRectal67.5 mg
SuppositoryRectal135 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0716 mg/mLALOGPS
logP6.2ALOGPS
logP2.8Chemaxon
logS-4ALOGPS
pKa (Strongest Acidic)5.14Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area40.13 Å2Chemaxon
Rotatable Bond Count15Chemaxon
Refractivity51.09 m3·mol-1Chemaxon
Polarizability16.59 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at September 18, 2017 21:14 / Updated at April 13, 2024 19:42